



BRIEF REPORT

First nosocomial outbreak of SME-4-producing *Serratia marcescens* in South America



Juana Vega^{a,c,*,◇}, Carlos H. Rodríguez^b, Ignacio Viscardi^a, Carlos Vay^b,
Silvina Torres^a, Emilce Tabares^a, Angela Famiglietti^b, Marcela Nastro^{b,*,◇}

^a Servicio de Microbiología, Departamento de Bioquímica, Hospital General 601-Hospital Militar Central "Cir My Dr Cosme Argerich", Argentina

^b Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, INFIBIOC, UBA, Argentina

^c Laboratorio de Bacteriología, Departamento de Bioquímica Clínica, Hospital de Clínicas José de San Martín, Facultad de Farmacia y Bioquímica, UBA, Argentina

Received 21 July 2022; accepted 17 February 2023

Available online 24 April 2023

KEYWORDS

SME-4;
Nosocomial outbreak;
Carbapenemases

PALABRAS CLAVE

SME-4;
Brote nosocomial;
Carbapenemasas

Abstract Carbapenemase-producing-*Serratia marcescens* isolates, although infrequent, are considered important nosocomial pathogens due to their intrinsic resistance to polymyxins, which limits therapeutic options. We describe a nosocomial outbreak of SME-4-producing *S. marcescens* in Buenos Aires city which, in our knowledge, represents the first one in South America.

© 2023 Asociación Argentina de Microbiología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Primer brote nosocomial por *Serratia marcescens* productora de SME-4 en Sudamérica

Resumen Los aislamientos de origen nosocomial de *Serratia marcescens* productores de carbapenemasa, si bien son infrecuentes, son considerados importantes patógenos debido a su resistencia intrínseca a las polimixinas, lo cual limita aún más las opciones terapéuticas. En

* Corresponding authors.

E-mail addresses: juanavega24@gmail.com (J. Vega), marcelanastro@hotmail.com (M. Nastro).

◇ These authors contributed equally to this study.

este trabajo se describe un brote nosocomial causado por *S. marcescens* portadora de carbapenemasa de tipo SME-4 en la Ciudad de Buenos Aires, el cual representaría el primero en Sudamérica.

© 2023 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Serratia marcescens is an opportunistic pathogen responsible for severe infections and nosocomial outbreaks. Although it does not carry acquired carbapenemase genes as frequently as other *Enterobacterales* such as *Klebsiella pneumoniae*, there are reports of KPC or MBL producing *S. marcescens* isolates worldwide⁶ and in Argentina^{5,11}.

SME serine enzymes are chromosomally-encoded and have been exclusively reported in *S. marcescens* isolates. They confer resistance to carbapenems but remain susceptible to extended spectrum cephalosporins and are inhibited by classical (clavulanic acid) and new inhibitors¹. To date, five SME variants (SME-1, -2, -3, -4 and -5) have been reported worldwide causing sporadic reports after their first detection in England in 1982^{2,10,13}. The first SME-4 variant was reported by the USA in Genbank under accession number KF481967; however, it has not been published yet. In South America, two clinical isolates were reported, one in Brazil in 2017³ and the other when our research group reported the first case in Argentina⁴ in 2019. In the present study, we describe a nosocomial outbreak of SME-4 producing *S. marcescens* in a public hospital of Buenos Aires city, Argentina, during the SARS-CoV-2 pandemic.

Samples belonging to four patients admitted to the Intensive Care Unit (ICU) at Hospital Militar Central Cosme Argerich of Buenos Aires city, in June 2021 were studied. The study was approved by the Ethics Committee of Hospital de Clínicas Jose de San Martin, Argentina. *S. marcescens* was recovered in the five isolates, of these, four (one isolate belonging to each patient) were subjected to further analysis as shown in Table 1. Identification was determined by matrix-assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS) and the Vitek-2 system (VITEK®2 GN) (VITEK®2 AST-N368), which was also used to perform the susceptibility testing of the isolates, according to the manufacturer's recommendations. Results were interpreted following the CLSI 2021 guidelines. A confirmatory test for detection of non-KPC class A carbapenemases with amoxicillin clavulanic (AMC) acid, was performed, as well as the Blue-Carba test¹² (Fig. 1).

Total DNA from the four isolates was extracted using the QIAamp DNA minikit (Qiagen, Les Ulis, France) following the manufacturer's instructions. The presence of *bla*_{SME} was investigated by PCR using specific primers (SME-1A: AGGAAGACTTTGATGGGAGG and SME-1B: GGCCAAATGACG-GCATAATC), which amplify an internal region of the gene, covering the 5 allelic variants described to date, followed by sequencing (Macrogen Inc., Seoul, Korea). Molecular typing was performed by REP-PCR¹⁴. A previous *S. marcescens* isolate harboring the SME-4 enzyme (Sm163) was included




Figure 1 Phenotypic detection of SME-4. Double disc-synergy test: boronic acid (300 µg)–imipenem (10 µg) and imipenem (30 µg)–amoxicillin clavulanic acid (30 µg).

in the molecular tests as positive control⁴, whereas an unrelated *S. marcescens* isolate was included as a negative control strain (NT strain).

The four patients were admitted to the ICU with SARS-CoV-2 pneumonia in the same month. Demographic information about the isolates is detailed in Table 1.

Sm1, Sm2, Sm3 and Sm4 showed the same susceptibility profile, which is detailed in Table 2. Carbapenem resistance and susceptibility to extended spectrum cephalosporins raised the alarm about a possible chromosomal class A carbapenemase that was detected phenotypically by the Blue-Carba test and the IMI-AMC-MER synergy test, which was positive in all the isolates. PCR amplification followed by sequencing of the SME gene confirmed the presence of the SME-4 variant. The four isolates displayed indistinguishable REP-PCR fingerprints (different from the NT strain pattern) confirming the suspicion of a nosocomial outbreak; the same pattern was also observed in control strain Sm163, which would suggest the possibility of a silent spread of a clone in our region.

The fact that the susceptibility profile of these isolates differs from the one observed in the most prevalent carbapenemases such as KPC or NDM makes its detection a challenge for clinical laboratories. Variability in susceptibility to meropenem and ertapenem has been described by some authors, together with the misdetection observed with some commercial phenotypic tests⁸. Considering that rapid molecular assays, such as the *bla*_{SME} gene, are not included in

Table 1 Demographic and molecular data of *Serratia marcescens* isolates.

Patient	Isolate	Enzyme	REP PCR-pattern	Date	Clinical specimen	Underlying diseases	Previous treatment	Outcome
1	Sm1	SME-4	A	4–7/6	TA, blood	SARS-CoV-2	MER, COL PTZ, LZD	Death
2	Sm2	SME-4	A	9/6	TA	SARS-CoV-2, dyslipidemia, smoking	MER, COL, AMS, VA	Favorable
3	Sm3	SME-4	A	22/6	TA	SARS-CoV-2, cancer, hyperc- holesterolemia, cardiovascular disease	MER, COL, AMC	Death
4	Sm4	SME-4	A	25/6	TA	SARS-CoV-2, obesity, hypothyroidism	MER, COL, AMC, CLA	Death

TA: tracheal aspirate; AMS: ampicillin sulbactam; AMC: amoxicillin/clavulanic acid; CLA: clarithromycin; VA: vancomycin; PTZ: piperacillin–tazobactam; LZD: linezolid; MER: meropenem; COL: colistin.

Table 2 Susceptibility profile of *S. marcescens* isolates.

Antimicrobial agent	MIC (μg/ml)			
	Sm1,2,3,4*	Interpretation	Sm163*	Interpretation
Ampicillin	≥32	R	>16	R
Amoxicillin/clavulanic	≥32	R	>16	R
Piperacillin/tazobactam	≤4	S	16/4	S
Cefazolin	≥64	R	>8	R
Cefoxitin	≤1	S	>16	R
Cefotaxime	≤1	S	NT	
Ceftriaxone	≤1	S	2	I
Ceftazidime	≤1	S	≤2	S
Cefepime	≤1	S	2	S
Ertapenem	NT		>1	R
Imipenem	≥16	R	>8	R
Meropenem	≥16	R	>8	R
Amikacin	≤2	S	≤8	S
Gentamicin	≤1	S	4	S
Trimethoprim/sulfamethoxazole	≤20	S	≤0.5/9.5	S
Ciprofloxacin	≤0.25	S	0.5	S
Colistin	≥16	R	>4	R
Fosfomycin	NT		>64	R

R: resistant; S: susceptible; NT: not tested.

* Phoenix system.

** Vitek system.

the routine tests available, we should be aware of the need to perform single gene PCR testing when observing these unusual resistance profiles to avoid a possible underestimation of this resistance mechanism.

Outbreaks of *S. marcescens* carrying SME variants are very infrequent; except for Hopkins' communication of seven isolates belonging to three patients in different areas of England⁸ and two clonally related isolates from two patients in different hospitals in Detroit⁷, only sporadic reports of SME-producing single isolates have been published. All SME-4 carriers reported so far have shown this enzyme to be chromosomally-encoded and the absence

of *S. marcescens* successful clones adapted to the hospital setting may contribute to this epidemiological profile. However, the finding of these isolates should be communicated to prevent future clonal spreads. In this particular case, infection control measures to prevent the future spread of the mechanism of resistance were implemented in the Intensive Care Unit; they included isolation in separate rooms, surveillance cultures and antimicrobial therapy.

The first *S. marcescens* isolates carrying SME-4 in our country were recovered from both a surveillance rectal swab and a catheter blood culture from a patient attended at the

University hospital of Buenos Aires city in the year 2016. The molecular studies performed on that isolate showed that the *bla*_{SME-4} gene was located on a SmarG11-1-like genomic island that may contribute to the mobilization of this gene among different *S. marcescens* isolates^{4,9}. No epidemiological link was found between the outbreak described in the present study and the previous clinical finding. Furthermore, it is of note that during these five years there had not been any reports of *S. marcescens* isolates with a similar phenotypic and genotypic profile in Argentina.

In the present work we describe the first nosocomial outbreak of four SME-4 producing *S. marcescens* isolates belonging to four patients in South America, which also represents the most extensive outbreak worldwide. We emphasize the need to be aware of the detection of these infrequent isolates to prevent the silent spread of this resistance mechanism in this nosocomial pathogen which represents a concern for clinicians due to the limited therapeutic options available.

Ethical approval

This work was carried out with bacterial isolates of clinical origin. All procedures performed in the study met the ethical standards of Hospital de Clinicas Jose de San Martin, B.A, Argentina (project UBACyT 20020130100167BA to Angela Famiglietti) and the 1964 Declaration of Helsinki and further amendments.

Funding

This work was supported by UBACyT 20020130100167BA to Angela Famiglietti.

Conflict of interest

None to declare.

References

- Biagi M, Shajee A, Vialichka A, Jurkovic M, Tan X, Wenzler E. Activity of imipenem-relebactam and meropenem-vaborbactam against carbapenem-resistant SME-producing *Serratia marcescens*. *Antimicrob Agents Chemother*. 2020;64, e02255–19.
- Bush K, Bradford PA. Epidemiology of β -lactamase-producing pathogens. *Clin Microbiol Rev*. 2020;33, e00047–19.
- Cayô R, Leme RC, Streling AP, Matos AP, Nodari CS, Chaves JR, Brandão JL, de Almeida MF, Carrareto V, de Castro Pereira MA, de Almeida JP, Ferreira DC, Gales AC. *Serratia marcescens* harboring SME-4 in Brazil: a silent threat. *Diagn Microbiol Infect Dis*. 2017;87:357–8.
- Dabos L, Patiño-Navarrete R, Nastro M, Famiglietti A, Glaser P, Rodriguez CH, Naas T. SME-4-producing *Serratia marcescens* from Argentina belonging to clade 2 of the *S. marcescens* phylogeny. *J Antimicrob Chemother*. 2019;74:1836–41.
- De Belder D, Lucero C, Rapoport M, Rosato A, Faccone D, Petroni A, Pasteran F, Albornoz E, Corso A, Gomez SA. Genetic diversity of KPC-producing *Escherichia coli*, *Klebsiella oxytoca*, *Serratia marcescens*, and *Citrobacter freundii* isolates from Argentina. *Microb Drug Resist*. 2018;24:958–65.
- Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1999–2005). *Diagn Microbiol Infect Dis*. 2006;56:367–72.
- Fairfax MR, Queenan AM, Lephart PR, Kaye KS, Dror M, Arnous N, Salimnia TT, Mitchell RA, Alangaden G, Salimnia H. Detection of 2 SME-1 carbapenemase-producing *Serratia marcescens* in Detroit. *Diagn Microbiol Infect Dis*. 2011;71:325–6.
- Hopkins KL, Findlay J, Meunier D, Cummins M, Curtis S, Kustos I, Mustafa N, Perry C, Pike R, Woodford N. *Serratia marcescens* producing SME carbapenemases: an emerging resistance problem in the UK? *J Antimicrob Chemother*. 2017;72:1535–7.
- Mataseje LF, Boyd DA, Delport J, Hoang L, Imperial M, Lefebvre B, Kuhn M, Van Caesele P, Willey BM, Mulvey MR. *Serratia marcescens* harbouring SME-type class A carbapenemases in Canada and the presence of blaSME on a novel genomic island, SmarG11-1. *J Antimicrob Chemother*. 2014;69:1825–9.
- Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase Sme-1, from *Serratia marcescens*. *Antimicrob Agents Chemother*. 1994;38:1262–70.
- Nastro M, Monge R, Zintgraff J, Vaulet LG, Boutureira M, Famiglietti A, Rodriguez CH. First nosocomial outbreak of VIM-16-producing *Serratia marcescens* in Argentina. *Clin Microbiol Infect*. 2013;19:617–9.
- Pires J, Novais A, Peixe L. Blue-carba, an easy biochemical test for detection of diverse carbapenemase producers directly from bacterial cultures. *J Clin Microbiol*. 2013;51:4281–3.
- Queenan AM, Shang W, Schreckenberger P, Lolans K, Bush K, Quinn J. SME-3, a novel member of the *Serratia marcescens* SME family of carbapenem-hydrolyzing beta-lactamases. *Antimicrob Agents Chemother*. 2006;50:3485–7.
- Singh G, Biswal M, Hallur V, Rao KL, Ray P, Gautam V, Appanavar SB, Taneja N. Utility of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for the rapid detection of nosocomial outbreaks of multidrug resistant organisms: experience at a tertiary care center in North India. *Indian J Med Microbiol*. 2015;33:221–4.